Does Low Dose Naltrexone Work for Fibromyalgia? What the Latest Research Shows
Low Dose Naltrexone has become one of the most discussed off-label options in fibromyalgia care. Patients often hear encouraging personal stories, while newer clinical studies and reviews offer a more cautious conclusion.
So, does LDN work for fibromyalgia?
The short answer: Research on Low Dose Naltrexone for fibromyalgia is mixed. Several small, earlier studies suggested that LDN may reduce pain for some patients. However, larger placebo-controlled trials and 2026 evidence reviews have not established that LDN consistently improves fibromyalgia pain or overall symptoms. LDN remains an off-label, patient-specific option, not a proven or FDA-approved fibromyalgia treatment.
That answer may feel less exciting than a promise. It is also more useful.
Patients deserve to know what the studies found, why the results conflict, what safety issues matter, and how a clinician may decide whether an individualized trial is reasonable.
What Is Fibromyalgia?
Fibromyalgia is a chronic condition associated with widespread pain, fatigue, disrupted sleep, cognitive symptoms often described as “fibro fog,” and emotional distress. The condition can significantly affect daily function and quality of life.
The American College of Rheumatology explains that fibromyalgia is not considered an inflammatory or autoimmune disease. Current research instead points to altered nervous-system processing of pain. Symptoms and treatment responses can vary substantially from one person to another.
That variability helps explain why patients and clinicians continue searching for additional options.
What Is Low Dose Naltrexone?
Naltrexone is an opioid antagonist, meaning it blocks opioid receptors. Standard oral naltrexone tablets are commonly available in a 50 mg strength and have FDA-approved substance-use-related indications.
“Low Dose Naltrexone,” or LDN, is an informal term used when naltrexone is prescribed at a much lower amount, often for an off-label purpose. A broad 2026 review described commonly studied LDN amounts as approximately 0.5 mg to 6 mg. There is no FDA-approved LDN product or FDA-approved naltrexone indication for fibromyalgia.
Because the patient-specific strength selected by a prescriber may not be commercially available, a compounding pharmacy may prepare the prescription. Compounded medications are not FDA approved, and FDA does not review a compounded preparation for safety, effectiveness, or quality before it reaches the patient. Compounding can still serve a legitimate clinical need when an FDA-approved product does not meet that need. Read the FDA’s explanation of pharmacy compounding.
Why Is LDN Considered for Fibromyalgia?
LDN has attracted interest because researchers have proposed effects beyond standard opioid-receptor blockade. Possible mechanisms involving pain signaling, glial cells, and immune pathways have been discussed.
These mechanisms remain hypotheses. A plausible biological explanation does not prove that a medication improves symptoms in patients.
The clinically important question is not simply, “Could LDN affect a pathway?” It is, “Does LDN produce a meaningful benefit compared with placebo in well-designed human trials?”
What Did the Early LDN Studies Find?
Early fibromyalgia studies were small but encouraging.
A 2013 randomized crossover study involving 31 women reported a greater reduction in baseline pain during LDN treatment than during placebo. That study helped generate significant interest in LDN, but its small size and crossover design limited the certainty of its findings. Review the 2013 study.
Small studies are useful for identifying a signal worth investigating. They are less reliable for determining how consistently a treatment will work across a larger and more diverse patient population.
What Did the Larger Trials Find?
The evidence became less certain as larger and more rigorous trials were completed.
The 2023 Crossover Trial
A randomized, double-blind, placebo-controlled crossover study evaluated LDN in people with fibromyalgia. The investigators did not find clinically relevant analgesic efficacy for LDN compared with placebo on the primary outcomes. Review the 2023 trial.
The 2024 FINAL Trial
The FINAL trial randomly assigned 99 women with fibromyalgia to naltrexone or placebo for 12 weeks. Average pain improved by 1.3 points in the naltrexone group and 0.9 points in the placebo group on a 0-to-10 scale. The between-group difference was 0.34 points and was not statistically significant.
The investigators concluded that naltrexone was not superior to placebo for reducing pain at the group level. The study was conducted at one center, included only women, and was not large enough to rule out the possibility that a smaller subgroup could respond differently. Still, it is one of the most rigorous LDN fibromyalgia trials available. Read the FINAL trial.
Why Did a 2024 Meta-Analysis Look More Positive?
A 2024 meta-analysis pooled four randomized trials with 222 participants and reported a statistically significant reduction in pain scores with LDN. It also found more vivid dreams and nausea with LDN than with placebo. Review the original meta-analysis.
In 2026, researchers published a re-analysis questioning several methodological decisions in that meta-analysis, including the combination of different pain scales and the handling of crossover-trial data. The original authors responded, and a corrigendum corrected part of the published analysis. Review the 2026 re-analysis and scientific exchange.
This does not mean every earlier finding should be ignored. It means the positive pooled estimate should not be treated as final proof.
LDN for Fibromyalgia, Evidence at a Glance
| Evidence | What it found | How to interpret it |
|---|---|---|
| 2013 randomized crossover study | Reported a greater reduction in pain with LDN than placebo | Encouraging, but only 31 women participated |
| 2023 randomized crossover study | Did not show clinically relevant analgesic efficacy on the primary outcomes | More cautious result, with sample-size and crossover-design limitations |
| 2024 FINAL trial | In 99 women, LDN was not superior to placebo for the primary pain outcome | One of the strongest individual trials, but still single-center and limited to women |
| 2024 meta-analysis | Pooled four trials and reported lower pain scores with LDN | Positive result, but later challenged over analytical methods and corrected in part |
| 2026 re-analysis | Suggested the pooled benefit may have been overestimated | Shows that the statistical interpretation remains disputed |
| 2026 broad evidence review | Reviewed 105 LDN studies, including 15 randomized trials across conditions, and found that early positive findings were rarely confirmed in placebo-controlled trials | Current evidence does not support routine LDN use across the studied conditions |
| 2026 Finnish evidence review | Concluded that LDN likely provides little to no benefit for fibromyalgia symptoms, with evidence downgraded for imprecision | A cautious professional-society interpretation of the blinded trial evidence |
What Does the Broadest 2026 LDN Review Say?
An April 2026 narrative review evaluated 105 human LDN studies across chronic pain, autoimmune and neuroimmune conditions, gastrointestinal disease, dermatology, post-infectious illness, mental health, and oncology. Only 15 were randomized controlled trials.
The authors found that positive results from early, uncontrolled studies were rarely replicated in placebo-controlled trials. They described LDN as generally well tolerated in the available studies, but concluded that the evidence did not support routine clinical use. Read the 2026 review in Advances in Therapy.
A March 2026 evidence review from the Finnish Medical Society Duodecim reached a similarly cautious conclusion for fibromyalgia, stating that LDN likely provides little to no benefit for fibromyalgia symptoms. The review rated the evidence as moderate but noted imprecision.
Does This Mean LDN Never Helps Anyone?
No. A clinical trial reports the average difference between groups. It cannot prove that no individual patient will ever perceive a benefit.
At the same time, personal improvement does not prove that the medication caused the change. Fibromyalgia symptoms can fluctuate. Expectations, concurrent treatments, sleep, stress, movement, and natural symptom variation may all affect how a patient feels.
The responsible conclusion is:
-
Some patients report improvement.
-
The average benefit has not been consistently confirmed in rigorous trials.
-
No reliable test currently identifies who will respond.
-
Treatment should include a defined goal and reassessment plan.
-
LDN should not be promoted as a cure or guaranteed solution.
This is where personalized medicine should become more disciplined, not less evidence-based.
How Could a Clinician Evaluate an Individual LDN Trial?
When a qualified clinician determines that an off-label LDN trial is appropriate, the treatment plan should define what success means before therapy begins.
Useful measures may include:
-
Average pain intensity
-
Sleep quality
-
Fatigue
-
Ability to complete daily activities
-
Frequency and severity of flares
-
Cognitive symptoms
-
Need for other symptom-relief medication
-
Side effects and adherence
A patient and clinician can then compare the same measures over an appropriate follow-up period. If there is no meaningful improvement, the plan should be reconsidered instead of continuing indefinitely because LDN is described online as “low risk.”
Patients should not independently increase, decrease, divide, stop, or restart a prescription.
What Are the Most Important LDN Safety Concerns?
The most important preventable safety concern is opioid exposure.
Naltrexone blocks opioid receptors. Current prescribing information lists oral naltrexone as contraindicated in patients receiving opioid analgesics, patients with current opioid dependence, and patients in acute opioid withdrawal. Starting naltrexone in someone who is physiologically dependent on opioids can precipitate severe withdrawal. Review the current DailyMed prescribing information.
Patients must disclose current or recent use of medications such as:
-
Hydrocodone
-
Oxycodone
-
Codeine
-
Morphine
-
Tramadol
-
Methadone
-
Buprenorphine
-
Fentanyl
-
Opioid-containing cough or diarrhea medications
Patients should also tell surgeons, dentists, emergency clinicians, and pharmacists that they take naltrexone because it can complicate opioid pain management.
Reported effects in LDN studies include vivid dreams, changes in sleep, nausea, headache, dizziness, fatigue, and gastrointestinal symptoms. Standard naltrexone labeling also contains warnings concerning liver injury and mood changes. A lower prescribed amount should not be interpreted as “risk free.”
How Does LDN Compare With Established Fibromyalgia Care?
LDN should not replace a comprehensive fibromyalgia evaluation.
The American College of Rheumatology emphasizes a combination of individualized medication, movement or exercise, sleep support, stress management, and treatment of related symptoms. The best plan depends on the patient’s pain pattern, sleep, fatigue, mental health, other conditions, current medications, and ability to function.
The goal is not to choose between “conventional” and “functional” medicine as competing identities. The goal is to build an evidence-informed, measurable, and patient-specific plan.
LDN may be discussed as one possible off-label component. It should not be presented as a substitute for diagnosis, appropriate follow-up, or established care.
Questions to Ask Before Considering LDN for Fibromyalgia
-
What symptoms are we specifically trying to improve?
-
How strong is the evidence for LDN for my situation?
-
Do any of my prescriptions or over-the-counter products contain an opioid?
-
Do I have an upcoming surgery, dental procedure, or other possible need for opioid pain treatment?
-
What side effects should I report?
-
How will pain, sleep, fatigue, function, and flares be measured?
-
When will treatment be reassessed?
-
What would cause us to stop or change the plan?
-
Is a compounded strength medically necessary?
-
Who should I contact with medication questions?
The Bottom Line
LDN remains an interesting but unproven off-label option for fibromyalgia.
Small early trials and some pooled analyses reported encouraging pain results. More rigorous placebo-controlled trials, a 2026 methodological re-analysis, and the broadest recent evidence reviews have been less positive.
That does not make LDN irrelevant. It makes honest screening, realistic expectations, measurable outcomes, and follow-up essential.
Patients considering LDN should review the evidence, every current medication, recent opioid exposure, relevant medical history, and treatment goals with a qualified healthcare professional. The question is not merely whether LDN is popular. The question is whether a carefully supervised, patient-specific plan produces meaningful improvement for that individual.
Explore Low Dose Naltrexone With Scripx Pharmacy
Scripx Pharmacy supports patient-specific compounded prescriptions, medication education, and pharmacist-guided care.
Scripx is licensed as a pharmacy in Texas, Florida, Michigan, Colorado, and Hawaii. Pharmacy services, telehealth evaluation, dispensing, and shipping eligibility may vary by state.
Learn the essentials first: [What Is Low Dose Naltrexone? Uses, Evidence, Safety, and Compounding]
Considering LDN? -- START NOW
Completing an evaluation does not guarantee eligibility, treatment, or a prescription. LDN use for fibromyalgia is off label. Compounded medications are not FDA approved.
Already have a prescription? Contact Scripx Pharmacy to discuss patient-specific compounding, prescription submission, medication questions, and available delivery options.
Scripx Pharmacy
601 W. FM 544, Suite 102
Murphy, TX 75094
Phone: 469-596-0341
Fax: 469-596-0412
This article is provided for general education and does not replace individualized medical advice. LDN use for fibromyalgia is off label. Compounded medications are not FDA approved.
Frequently Asked Questions
Is Low Dose Naltrexone FDA approved for fibromyalgia?
No. Naltrexone is FDA approved for specific substance-use-related indications. Low-dose use for fibromyalgia is off label, and a patient-specific compounded LDN preparation is not FDA approved.
Does LDN reduce fibromyalgia pain?
The evidence is mixed. Small early trials and some meta-analyses reported pain improvement, but larger and more rigorous placebo-controlled trials did not show that LDN was superior to placebo for the primary pain outcomes.
Why do some people say LDN works if trials are negative?
Some individuals may experience improvement, but fibromyalgia symptoms also fluctuate over time. Personal experience is important for care, but it cannot establish how reliably a treatment works across a population.
How long does LDN take to work for fibromyalgia?
There is no validated timeline that predicts response for an individual patient. Published trials have evaluated different treatment periods. A clinician should establish a follow-up plan and measurable goals instead of promising a fixed response date.
What are common LDN side effects?
Vivid dreams, sleep changes, nausea, headache, dizziness, fatigue, and gastrointestinal symptoms have been reported. Patients should discuss persistent, severe, or worsening symptoms with the prescribing team.
Can LDN be taken with opioid pain medication?
Naltrexone blocks opioid receptors and may block pain relief or precipitate severe withdrawal in an opioid-dependent person. Patients should not combine LDN with opioids or manage a transition without direct medical supervision.
Is fibromyalgia an autoimmune disease?
The American College of Rheumatology states that fibromyalgia is not considered an inflammatory or autoimmune disease. Research suggests that altered nervous-system processing of pain is involved.
Is compounded LDN the same as standard oral naltrexone?
Both contain naltrexone as the active ingredient, but they may differ in prescribed strength, dosage form, excipients, FDA status, and intended use. Standard 50 mg tablets are FDA approved for specific indications. A compounded LDN preparation is not FDA approved.